infrequent assessment for disease progression could lead to overe

infrequent assessment for disease progression could lead to overestimating PFS. In this study, the median PFS for sunitinib was 7. 3 months, and the median OS was 14. 5 months. In Y-27632 DOCA the EAP, the median PFS for sunitinib was 10. 9 months, and the median OS was 18. 4 months. Median duration of sunitinib therapy in this study was 6. 6 months while median follow up duration in the EAP was 11. 6 months. For patients receiving sorafenib in this study, the median PFS was 7. 3 months, and the median OS was 15. 0 months. In the EAP, the median PFS was 5. 5 months, and the median OS was 11. 5 months. Median treatment duration for sorafenib in this study was 5. 8 months while in the EAP it was 2. 8 months. Based on these qualitative observations, the survival outcomes appear to be generally consistent with those from the EAPs.

This study has several limitations. First, the study sample was relatively Inhibitors,Modulators,Libraries small and came from a single ter tiary oncology center in Italy, limiting generalizability of the study results. Future studies are needed to perform similar evaluations in patients with mRCC in other countries. Finally, because this is an observational study, the lack of randomization and the potential resulting selection bias limit the studys ability to compare between agents. Conclusions In this study, patients receiving sunitinib or sorafenib frequently experienced treatment related adverse events. Progressive disease was the most common reason for first line MKI discontinuation, while adverse events were the most common reasons for treatment interrup tions and dose reductions.

While the rates of specific adverse events were different in the current study com pared with the EAPs, the results from this retrospective study in a real world observational setting corroborate findings from the EAPs that adverse events are com monly associated with sunitinib and sorafenib treatment. Together, these results may suggest a need for addi tional effective and more tolerable Inhibitors,Modulators,Libraries treatments for mRCC. Background Renal cancer is among the tenth most common cancers and its incidence has increased constantly in recent dec ades. Two thirds of patients have no evidence of dis tant metastasis at diagnosis, Inhibitors,Modulators,Libraries and radical surgery can be curative. However, just a fraction of these patients are effectively cured by surgery as recurrence occurs in a high proportion of cases.

In the last Inhibitors,Modulators,Libraries 30 years, only a few drugs have shown some activity against advanced renal cancer. Initially immunomodulators, namely, interferon and interleukin 2, were used to control metastatic disease Inhibitors,Modulators,Libraries and, in unpredictable instances, could stabilize the disease for years or even eliminate it completely. The existence of rare but exceptional results with immunomodulators in metastatic patients triggered initiation of mostly trials testing these drugs, combined or not with antineoplastic agents in the adjuvant setting. Some trials tested immunotherapy or vaccines derived from tumor cells.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>